Abstract: Provided herein are trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and at least two of the antigen binding sites specifically bind an interleukin-4 (IL-4) polypeptide and an interleukin-13 (IL-13) polypeptide, respectively. In some embodiments, the third antigen binding site specifically binds an OX40L polypeptide, an interleukin-17 (IL-17) polypeptide, or a natural killer group 2D (NKG2D) polypeptide. The disclosure also relates to nucleic acid molecules, expression vectors, host cells, compositions (e.g., pharmaceutical compositions), methods of production, methods of use, and uses related thereto.

Abstract: The present disclosure relates to dsRNAs targeting ANGPTL8, methods of inhibiting ANGPTL8 gene expression, and methods of treating one or more conditions associated with ANGPTL8 gene expression.

Abstract: The present disclosure relates to dsRNAs targeting ANGPTL3, methods of inhibiting ANGPTL3 gene expression, and methods of treating one or more conditions associated with ANGPTL3 gene expression.

Abstract: Provided herein, inter alia, are dsRNA compositions targeting PCSK9, methods of inhibiting PCSK9 gene expression, and methods of treating one or more diseases associated with PCSK9 gene expression.

Abstract: The present disclosure relates to dsRNAs targeting ANGPTL8, methods of inhibiting ANGPTL8 gene expression, and methods of treating one or more conditions associated with ANGPTL8 gene expression.